Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

CROI 2015: PrEP Use Rising in San Francisco, but Scale-Up Could Cut New Infections

Use of Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, better known as PrEP, is increasing in San Francisco, but it is still only reaching about one-third of people who could benefit, and wider use could reduce new HIV infections by 70%, according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: PrEP Stops 86% of HIV Infections in PROUD Study

A study of pre-exposure prophylaxis (PrEP), the English PROUD study, demonstrated the highest effectiveness yet seen for this method of HIV prevention, the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle heard today. The effectiveness was 86%; for every 20 infections that might have occurred in participants, 17 were stopped by PrEP. 

alt

Read more:

CROI 2015: European PrEP Studies Find High and Equivalent HIV Protection

The UK PROUD study of once-daily Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis (PrEP), and the French Ipergay study of "on-demand" PrEP taken before and after sex, both saw an 86% reduction in new HIV infections, researchers reported at the at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) this week in Seattle.

PrEP Stops 86% of HIV Infections in PROUD Study

On-Demand PrEP Prevents 86% of HIV Infections in Ipergay

alt

CROI 2015: On-Demand PrEP Prevents 86% of HIV Infections in Ipergay

A French and Canadian study of pre-exposure prophylaxis (PrEP) presented today at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle found that the HIV infection rate for participants taking an intermittent PrEP regimen was 86% lower than for people taking an inactive placebo. Extraordinarily, this is exactly the same level of effectiveness that was demonstrated in the English PROUD study, whose outcomes were presented 15 minutes before Ipergay. Ipergay is a very different study than PROUD and it is encouraging that 2 different ways of taking PrEP have both proved effective in gay men, at least in a western European context.

alt

Read more:

Study of Truvada PrEP and Tenofovir Vaginal Gel Misses Mark Due to Low Adherence

The final published report in the New England Journal of Medicine from the VOICE trial of HIV prevention for women in 3 African countries mainly reinforces what conference presentations have already shown: this ambitious trial failed to demonstrate the effectiveness of either oral pre-exposure prophylaxis (PrEP) or of a tenofovir-containing vaginal microbicide gel, and the reason for this was that only 25%-30% of women actually used the study product, despite 88% claiming they did so. The gel, however, may have stopped 2 out of 3 infections among women who used it.

alt

Read more: